Zahid H Siddik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5665869/publications.pdf

Version: 2024-02-01

34 papers

4,257 citations

411340 20 h-index 29 g-index

35 all docs

35 docs citations

35 times ranked

8271 citing authors

#	Article	IF	CITATIONS
1	Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents. Cancer Chemotherapy and Pharmacology, 2020, 85, 1129-1140.	1.1	2
2	Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7021-7029.	3. 3	42
3	Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill. Molecular Pharmacology, 2020, 97, 237-249.	1.0	4
4	Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights. Seminars in Cancer Biology, 2019, 58, 65-79.	4.3	94
5	Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation. Molecular Cancer Research, 2017, 15, 328-339.	1.5	12
6	New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status. Oncotarget, 2017, 8, 490-505.	0.8	61
7	Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. Oncotarget, 2017, 8, 10905-10918.	0.8	15
8	Frontispiz: Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angewandte Chemie, $2016,128,.$	1.6	0
9	Frontispiece: Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angewandte Chemie - International Edition, 2016, 55, .	7.2	О
10	Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angewandte Chemie, 2016, 128, 12816-12821.	1.6	13
11	Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Angewandte Chemie - International Edition, 2016, 55, 12626-12631.	7.2	61
12	Photoinduced Reduction of PtlVwithin an Anti-Proliferative PtlV-Texaphyrin Conjugate. Chemistry - A European Journal, 2014, 20, n/a-n/a.	1.7	17
13	Apoptosis in Cancer. , 2014, , 357-390.		4
14	Recent Developments in Texaphyrin Chemistry and Drug Discovery. Inorganic Chemistry, 2013, 52, 12184-12192.	1.9	65
15	ATP11B mediates platinum resistance in ovarian cancer. Journal of Clinical Investigation, 2013, 123, 2119-2130.	3.9	56
16	Tissue Platinum Concentration and Tumor Response in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3345-3352.	0.8	81
17	A texaphyrin–oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells. MedChemComm, 2012, 3, 1275.	3.5	27
18	Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochemical Pharmacology, 2012, 83, 1049-1062.	2.0	60

#	Article	IF	CITATIONS
19	The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog. Gynecologic Oncology, 2011, 122, 402-409.	0.6	49
20	Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin–platinum conjugate. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1701-1705.	1.0	25
21	Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemotherapy and Pharmacology, 2010, 65, 427-436.	1.1	10
22	Targeting p21-Dependent Pathways for Cell Death in Cancer Therapy. , 2010, , 199-213.		0
23	Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clinical Cancer Research, 2009, 15, 3770-3780.	3.2	128
24	Gadolinium texaphyrin (Gd-Tex)-malonato-platinum conjugates: Synthesis and comparison with carboplatin in normal and Pt-resistant cell lines. Dalton Transactions, 2009, , 10834.	1.6	16
25	Drug Resistance and the Tumor Suppressor p53: The Paradox of Wild-Type Genotype in Chemorefractory Cancers. , 2009, , 209-231.		2
26	Elevated Glutathione Levels Confer Cellular Sensitization to Cisplatin Toxicity by Up-Regulation of Copper Transporter hCtr1. Molecular Pharmacology, 2008, 74, 697-704.	1.0	63
27	Cisplatin Resistance. , 2006, , 283-307.		7
28	Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene, 2005, 24, 2929-2943.	2.6	231
29	Increased sensitivity of a metastatic model of prostate cancer to a novel tetravalent platinum analog. Prostate, 2005, 62, 91-100.	1.2	10
30	Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. Journal of Cancer Research and Clinical Oncology, 2003, 129, 709-718.	1,2	29
31	Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003, 22, 7265-7279.	2.6	2,838
32	Chemical and Biological Studies on a Series of Novel (trans-(1R,2R)-,trans-(1S,2S)-,) Tj ETQq0 0 0 rgBT /Overlock 1997, 40, 112-116.	10 Tf 50 2 2.9	27 Td (andcis 52
33	Synthesis and antitumor activity of 1,2-diaminocyclohexane platinum(IV) complexes. Journal of Inorganic Biochemistry, 1994, 54, 39-47.	1.5	20
34	Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Analytical Biochemistry, 1987, 163, 21-26.	1.1	137